Developing Safe & Efficacious mRNA, CircRNA & SaRNA Medicines With Smarter Design Optimization, Targeted Delivery & Scalable Manufacturing for Clinical & Commercial Readiness
South Korea’s mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in clinical-stage vaccines. Also, with the growing momentum of ARPA-H initiatives focused on personalized mRNA cancer therapies and strong government backing continues to drive the development of safer, more effective RNA-based medicines.
Amid this innovation, the World RNA-Based Therapeutics & Vaccines Summit returns to South Korea for its second year, highlighting breakthroughs in mRNA design, therapeutic pipelines, targeted delivery, and solutions to key manufacturing and analytical challenges. This is your chance to de-risk your program strategies, unlock insights from international leaders, and forge networks to develop better RNA medicines for patients faster.
As Korean RNA and vaccine companies strive to establish partnerships, out-license their assets, or create co-development collaborations with global companies, join 80+ mRNA therapeutic and vaccine developers to differentiate your technology and learn how to generate meaningful data to open up the possibilities of future partnerships.
Supported by:
전문 연사 발표
Attending Companies Include
참석 기업에는 다음이 포함됩니다
Download the Official Agenda to Explore:
공식 아젠다를 다운로드하여 다음 내용을 확인하세요:
- Your one-stop forum to de-risk, develop, and collaborate to advance RNA therapeutics and vaccines
- Insights from 20+ Korean-based and international speakers
- 20+ Data-driven case-studies across RNA Discovery to clinic and manufacturing
- Unrivalled networking opportunities with experts
World-Class Speaker Faculty Includes:
전문 연사 발표
This meeting will serve as a key scientific catalyst, accelerating the expansion of mRNA-based therapeutics into cancer vaccines, immuno-oncology, and autoimmune disease treatments.
Kug Hwa Lee, Director, MediciBio
I think this is a great opportunity to learn about personalized cancer vaccine development. There are a few companies working on PCV and there are lots of challenges especially in manufacturing, regulation, cost, etc
Seihwan Jeong, Project Leader - Cancer Immunotherapy, LG Chem
This meeting unites the RNA therapeutics and vaccines community in one powerful forum - driving collaboration, shaping the next phase of growth, and accelerating progress across science, manufacturing, regulation, and business.
Sunjong Kwon, Head of R&D Centre, EyeGene
Official Partners:
공식 파트너
Other Events in the Series
관련 행사 둘러보기
Explore the Agenda
Hear the latest technology innovations taking place within South Korea and gain exclusive insights on the progress in development globally.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean Advanced Therapeutics leaders.
Join Biopharma Experts
Be part of the hottest conversations with like-minded scientists, C-level executives, heads, managers, VPs, and more across discovery, clinical and CMC functions.